πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 121 of 173

  1. US 8030447

    Substrate peptide sequences for plague plasminogen activator and uses thereof

    Expires Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8030297

    Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders

    Expires Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8029826

    Chlorite in the treatment of neurodegenerative disease

    Expires Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8026263

    Methods for inhibiting neoproliferative changes in blood vessel walls

    Expires Mon Sep 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8026284

    Enterically coated cystamine, cysteamine and derivatives thereof

    Expires Mon Sep 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8025891

    Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia

    Expires Mon Sep 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8026226

    Medical and nutritional applications of highly refined cellulose

    Expires Mon Sep 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8021874

    Very long chain polyunsaturated fatty acids, methods of production, and uses

    Expires Mon Sep 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8021831

    Taxane chemosensitivity prediction test

    Expires Mon Sep 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8021673

    Proteins with repetitive Bacterial-Ig-like (Big) domains present in Leptospira species

    Expires Mon Sep 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8021644

    Methods for measuring rates of reverse cholesterol transport in vivo, as an index of anti-atherogenesis

    Expires Mon Sep 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8022040

    Hydroxyapatite-binding peptides for bone growth and inhibition

    Expires Mon Sep 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8022052

    Inhibition of PPAR gamma expression by specific osteogenic oxysterols

    Expires Mon Sep 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8017151

    Amphiphilic polymer-protein conjugates and methods of use thereof

    Expires Mon Sep 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8017155

    Methods for encapsulation of biomacromolecules in polymers

    Expires Mon Sep 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8017321

    Gefitinib sensitivity-related gene expression and products and methods related thereto

    Expires Mon Sep 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8017135

    Lipid-drug conjugates for local therapy of eye diseases

    Expires Mon Sep 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8012739

    Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA synthetase pairs

    Expires Mon Sep 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8012476

    Molecules with extended half-lives, compositions and uses thereof

    Expires Mon Sep 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8013015

    Small molecule inhibitors of ghrelin O-acyltransferase

    Expires Mon Sep 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8007787

    Human cystathionine Ξ²-synthase variants and methods of production thereof

    Expires Mon Aug 25 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8008510

    Metalloprotein inhibitors

    Expires Mon Aug 25 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8008353

    Methods for modulating macrophage proliferation using polyamine analogs

    Expires Mon Aug 25 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8008308

    Phosphonate compounds

    Expires Mon Aug 25 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8007804

    Complement receptor 2 targeted complement modulators

    Expires Mon Aug 25 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8007774

    Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same

    Expires Mon Aug 25 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8007778

    Use of calcium binding proteins to improve cardiac contractile function

    Expires Mon Aug 25 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8003692

    Methods and compositions to inhibit edema factor and adenylyl cyclase

    Expires Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8003693

    Modulation of anxiety through blockade of anandamide hydrolysis

    Expires Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8003622

    Peptide biosynthesis and pain therapy

    Expires Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7998490

    Genes of an otitis media isolate of nontypeable Haemophilus influenzae

    Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7998928

    Method of treatment of type-1 diabetes with a humanin analogue

    Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7998923

    Bioactivation of particles

    Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7999082

    Anti-factor B antibodies

    Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7998481

    Modulation of NKG2D for treating or preventing solid organ allograft rejection

    Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7998926

    Dimerized T-cell receptor fragment, its compositions and use

    Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7999079

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7994143

    Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates

    Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7993865

    Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen

    Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7993648

    Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody

    Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7993867

    Diagnosis, prevention and treatment of crohn's disease using the OmpC antigen

    Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7994313

    Unsolvated benzodiazepine compositions and methods

    Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7994320

    Narcistatin prodrugs

    Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7994132

    Peptides for treatment of scleroderma

    Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7994226

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7994150

    Micro-RNAs that modulate smooth muscle proliferation and differentiation and uses thereof

    Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7993866

    Diagnosis, prevention and treatment of crohn's disease using the OmpC antigen

    Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7988685

    Hydrogel compositions, devices, and microscale components

    Expires Mon Jul 28 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.